;
Skip to main content
Home > Week in Review > Preclinical Results

Chronological Index of : Preclinical Results

 Current Issue
  • Idenix preclinical data

    Idenix Pharmaceuticals Inc. (NASDAQ:IDIX), Cambridge, Mass. Product: IDX21437 Business: Infectious Indication: Treat HCV infection In HCV cell-based assays, IDX21437 selectively inhibited HCV replicons. Idenix also said…

    Published on 4/7/2014
  • Isis Pharmaceuticals preclinical data

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Product: ISIS-HBVRx (formerly ISIS-GSK3Rx) Business: Infectious Indication: Treat HBV infection In a mouse model of HBV infection, subcutaneous doses of >=11 …

    Published on 4/7/2014
  • Patrys preclinical data

    Patrys Ltd. (ASX:PAB), Melbourne, Australia Product: PAT-LM1 Business: Cancer Indication: Treat lymphoma In vitro, PAT-LM1 induced cell death in mantle cell lymphoma (MCL) and histiocytic lymphoma cells. Patrys declined…

    Published on 4/7/2014
  • Novogen preclinical data

    Novogen Ltd. (ASX:NRT; NASDAQ:NVGN), Hornsby, Australia Product: Trilexium (Trx-1) Business: Cancer Indication: Treat ovarian cancer In a mouse xenograft model of ovarian cancer, Trx-1 significantly reduced tumor growth…

    Published on 3/31/2014
  • BioCryst preclinical data

    BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), Durham, N.C. Product: BCX4430 Business: Infectious Indication: Treat Marburg virus infection In cynomolgus macaques infected with a lethal dose of Marburg virus, twice-daily …

    Published on 3/17/2014
  • Synta preclinical data

    Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Lexington, Mass. Product: HDC docetaxel (STA-9183) Business: Cancer Indication: Treat solid tumors In mouse xenograft models of triple-negative breast cancer (TNBC) and non-…

    Published on 3/10/2014
  • Synta preclinical data

    Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Lexington, Mass. Product: HDC SN-38 (STA-12-8666) Business: Cancer Indication: Treat solid tumors In mouse xenograft tumor models, STA-12-8666 safely delivered >10 times …

    Published on 3/10/2014
  • Angiochem preclinical data

    Angiochem Inc., Montreal, Quebec Product: ANG2002 Business: Neurology Indication: Treat pain In rat models of neuropathic and bone cancer pain, 0.05 mg/kg ANG2002 significantly reduced pain behaviors vs. vehicle-treated…

    Published on 3/3/2014
  • AngioGenex preclinical data

    AngioGenex Inc. (Pink:AGGX), New York, N.Y. Product: Idantirx (AGX-51) Business: Cancer Indication: Treat cancer In a mouse model of breast cancer, twice-daily AGX-51 significantly blocked tumor growth at a dose <7 …

    Published on 3/3/2014
  • Biokine, BioLineRx preclinical data

    Biokine Therapeutics Ltd., Tel Aviv, Israel BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel Product: BL-8040 (formerly BKT-140) Business: Cancer Indication: Treat chronic myelogenous leukemia (CML) In …

    Published on 3/3/2014
  • Epizyme, Eisai preclinical data

    Epizyme Inc. (NASDAQ:EPZM), Cambridge, Mass. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: EPZ-6438, E7438 Business: Cancer Indication: Treat non-Hodgkin's lymphoma (NHL) In a mouse xenograft model of enhancer of …

    Published on 3/3/2014
  • Marina Biotech, Mirna preclinical data

    Marina Biotech Inc. (OTCQX:MRNA), Bothell, Wash. Mirna Therapeutics Inc., Austin, Texas Product: MRX34, miR-34 (formerly miR-Rx34) Business: Cancer Indication: Treat non-small cell lung cancer (NSCLC) and hepatocellular…

    Published on 3/3/2014
  • Vivolux preclinical data

    Vivolux AB, Uppsala, Sweden Product: VLX600 Business: Cancer Indication: Treat solid tumors In a mouse xenograft model of colorectal cancer, IV 16 mg/kg VLX600 given every 3 days for 16 days significantly inhibited …

    Published on 3/3/2014
  • BerGenBio, Rigel preclinical data

    BerGenBio A/S, Bergen, Norway Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Product: BGB324 (formerly R428) Business: Cancer Indication: Treat non-small cell lung cancer (NSCLC) In a mouse …

    Published on 2/24/2014
  • Genfit preclinical data

    Genfit S.A. (Euronext:ALGFT), Lille, France Product: GFT505 Business: Cancer Indication: Treat cancer In vitro, GFT505 blocked proliferation of cancer cells in the majority of 21 human cancer cell lines. The cell lines …

    Published on 2/24/2014
  • Innovimmune preclinical data

    Innovimmune Biotherapeutics Inc., New York, N.Y. Product: INV-17 Business: Autoimmune Indication: Prevent multiple sclerosis (MS) In a mouse model of chronic progressive experimental autoimmune encephalomyelitis (EAE), …

    Published on 2/17/2014
  • Intellect Neurosciences preclinical data

    Intellect Neurosciences Inc. (OTCBB:ILNS), New York, N.Y. Product: TauC3 Business: Neurology Indication: Treat Alzheimer's disease (AD) In a transgenic mouse model of AD that exhibits both beta amyloid and tau …

    Published on 2/17/2014
  • MediciNova, Kyorin preclinical data

    MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875), San Diego, Calif. Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569), Tokyo, Japan Product: MN-001, KCA-757 Business: Hepatic Indication: Treat non-alcoholic steatohepatitis (NASH) …

    Published on 2/17/2014
  • Mast Therapeutics preclinical data

    Mast Therapeutics Inc. (NYSE-M:MSTX), San Diego, Calif. Product: Purified poloxamer 188 (MST-188) (formerly ANX-188) Business: Cardiovascular Indication: Treat chronic heart failure In a preclinical model of chronic …

    Published on 2/10/2014
  • Arcturus Therapeutics preclinical data

    Arcturus Therapeutics Inc., San Diego, Calif. Product: RNAi therapeutic targeting transthyretin (TTR) Business: Endocrine/Metabolic Indication: Treat transthyretin (TTR)-mediated amyloidosis In non-human primates, a …

    Published on 2/3/2014
  • BerGenBio, Rigel preclinical data

    BerGenBio A/S, Bergen, Norway Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Product: BGB324 (formerly R428) Business: Cancer Indication: Treat chronic myelogenous leukemia (CML) In a mouse model …

    Published on 1/20/2014
  • MacroGenics preclinical data

    MacroGenics Inc. (NASDAQ:MGNX), Rockville, Md. Product: MGD006 (CD3xCD123 DART molecule) Business: Cancer Indication: Treat acute myelogenous leukemia (AML) In mice infused with primary AML xenografts, MGD006 led to a &…

    Published on 1/20/2014
  • Teva, Sanofi preclinical data

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Copaxone glatiramer acetate Business: Autoimmune Indication: Treat multiple sclerosis (MS) A …

    Published on 1/20/2014
  • Neumedicines preclinical data

    Neumedicines Inc., Pasadena, Calif. Product: HemaMax (NMIL 12-1) Business: Other Indication: Treat acute radiation syndrome (ARS) In non-human primates, a single low-dose subcutaneous injection of HemaMax significantly …

    Published on 1/13/2014
  • Alnylam preclinical data

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Product: ALN-ANG Business: Endocrine/Metabolic Indication: Treat genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia In a mouse model of …

    Published on 1/6/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993